Introduction:
PulseSight Therapeutics SAS, a new biotech company in ophthalmology, has been launched with seed financing from Pureos Bioventures and ND Capital. The company aims to develop non-viral gene therapies combined with minimally invasive delivery technology to address age-related macular diseases (AMD), including wet and dry AMD and geographic atrophy (GA), which often lead to vision loss in the elderly population. PulseSight’s proprietary electro-transfection system has shown promising results in Phase I/II clinical studies, demonstrating safety and clinical benefits in targeting major eye diseases.
- PulseSight Therapeutics SAS has launched with seed financing from Pureos Bioventures and ND Capital.
- The company aims to develop non-viral gene therapies combined with minimally invasive delivery technology.
- PulseSight’s electro-transfection system targets major eye diseases with high accuracy and has shown promising results in Phase I/II clinical studies.
- PulseSight’s lead program, PST-809, offers a multifaceted approach to treating wet AMD, reducing the frequency of anti-VEGF injections.
- PulseSight’s second program, PST-611, targets geographic atrophy in late-stage dry AMD and holds therapeutic promise for other retinal disorders.
Conclusion:
PulseSight Therapeutics SAS’s innovative non-viral gene therapy approach, coupled with its minimally invasive delivery technology, has the potential to disrupt the field of ophthalmology and provide effective treatments for age-related macular diseases. The company’s lead program, PST-809, offers new possibilities for treating wet AMD, while the second program, PST-611, shows promise in addressing geographic atrophy and other retinal disorders. With the support of prominent venture capital investors, PulseSight Therapeutics SAS is well-positioned to make significant advancements in the field and improve the lives of individuals suffering from vision loss.
